Background. Esophageal squamous cell carcinoma was treated by operation and chemoradiotherapy. However, the prognosis of most patients is poor after treatment, and most studies have shown that FGF2 and its receptor (FGFR) are involved in the development of various malignant tumors. FGF2 plays an important role in tumor progression and malignancy. In this study, the immunohistochemistry of FGF2, FGFR3, and FGFBP1 was used to further verify the expression of the three proteins in 172 patients with esophageal squamous cell carcinoma (ESCC) who had not received preoperative chemoradiotherapy and its effect on the prognosis of ESCC. Methods. (1) test was used to analyze the relationship between proteins and clinicopathological parameters. Survival analysis was used to investigate the effect of three proteins on prognosis. (2) Paired sample -test was used to analyze the mRNA expression of the three proteins in fresh ESCC tissues and adjacent normal tissues. Results. FGF2 was correlated with tumor size (), gender (), and lymph metastasis () in ESCC tissues. The high expression of FGFR3 was associated with tumor differentiation ( and ), lymph node metastasis ( and ), and race ( and ). The high expression of FGFBP1 was significantly associated with the degree of tumor differentiation (), age (), and lymph node metastasis () of ESCC patients. The expression of FGF2, FGFR3, and FGFBP1-mRNA in ESCC tissues was significantly higher than that in adjacent tissues (, , and ). Patients with high expression of FGF2, FGFBP1, and FGFR3 had poor prognosis. There was a weak positive correlation between FGF2 and FGFBP1, as well as FGFR. Conclusion. The FGF2-FGFR3 axis may promote the progression of esophageal squamous cell carcinoma. The FGF2-FGFR3 axis may be a new direction of targeted therapy for esophageal squamous cell carcinoma. FGF2 and FGFR3 may be used as prognostic markers of esophageal squamous cell carcinoma.

中文翻译：

---

FGF2、FGFR3、FGFBP1在食管鳞状细胞癌中的表达及预后价值

背景。食管鳞状细胞癌采用手术和放化疗治疗。但大多数患者治疗后预后较差，多数研究表明FGF2及其受体（FGFR）参与了多种恶性肿瘤的发生发展。FGF2在肿瘤进展和恶性肿瘤中起重要作用。本研究采用FGF2、FGFR3和FGFBP1的免疫组化方法进一步验证3种蛋白在172例未接受术前放化疗的食管鳞状细胞癌（ESCC）患者中的表达及其对ESCC预后的影响。方法。(1)检验用于分析蛋白质与临床病理参数的关系。生存分析用于研究三种蛋白质对预后的影响。(2)配对样本-试验分析三种蛋白在新鲜ESCC组织和邻近正常组织中的mRNA表达。结果。FGF2与肿瘤大小相关（),性别 ()和淋巴转移 ()在 ESCC 组织中。FGFR3的高表达与肿瘤分化有关（和),淋巴结转移 (和)和种族 (和）。FGFBP1的高表达与肿瘤分化程度显着相关（),年龄 (）和淋巴结转移（)的 ESCC 患者。ESCC组织中FGF2、FGFR3和FGFBP1-mRNA的表达明显高于癌旁组织。, ,和）。FGF2、FGFBP1和FGFR3高表达的患者预后较差。FGF2和FGFBP1以及FGFR之间存在弱正相关。结论。FGF2-FGFR3轴可能促进食管鳞状细胞癌的进展。FGF2-FGFR3轴可能是食管鳞状细胞癌靶向治疗的新方向。FGF2和FGFR3可用作食管鳞状细胞癌的预后标志物。